Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase 2 for endometriosis, while GS-073 is ready to enter clinical phase 1 for chronic inflammatory pain.